


Supplementary Information for


Targeting inflammasome/IL-1 pathways for cancer immunotherapy

Beichu Guo^{1,2,*}, Shunjun Fu¹, Jinyu Zhang¹, Bei Liu^{1,2}, Zihai Li^{1,2}

1 Department of Microbiology and Immunology, 2 Hollings Cancer Center, Medical University of South Carolina (MUSC), Charleston, South Carolina 29425-5040. United States of America.



Supplemental Figure S1. Inflammasome activation in tumor microenvironments. Western Blot analysis of tumor tissues from WT, NLRP3 KO and caspase-1 KO mice injected orthotopically with EO771 tumor cells. Tumor tissues were harvested, homogenized, and analyzed by Western Blot with anti-IL-1 β or anti-caspase-1 antibodies for caspase 1 and IL-1 β processing.



Supplemental Figure S2. IL-1 β induces CCL2 expression in macrophages and tumor cells. RT-PCR analysis of CCL2 expression in macrophage cell line RAW 264.7 and breast cancer cell line EO771 treated with IL-1 β .